Similar articles

• Piracetam: a review of pharmacological properties and clinical uses.

  Winblad B. Winblad B. CNS Drug Rev. 2005 Summer;11(2):169-82. doi: 10.1111/j.1527-3458.2005.tb00268.x. CNS Drug Rev. 2005. PMID: 16007238 Free PMC article. Review.
• Piracetam and acetamide in sickle-cell disease.

  de Araujo JT, Nero GS. de Araujo JT, et al. Lancet. 1977 Aug 20;2(8034):411. Lancet. 1977. PMID: 70630 No abstract available.
• [Trial prevention of vaso-occlusive crises in homozygote sickle cell anemia using piracetam].

  Sonnet J, Gini EK, Cornu G. Sonnet J, et al. Ann Soc Belg Med Trop. 1985;65(1):77-84. Ann Soc Belg Med Trop. 1985. PMID: 4004377 French. No abstract available.
• Use of piracetam improves sickle cell deformability in vitro and in vivo.

  Gini EK, Sonnet J. Gini EK, et al. J Clin Pathol. 1987 Jan;40(1):99-102. doi: 10.1136/jcp.40.1.99. J Clin Pathol. 1987. PMID: 3818978 Free PMC article.
• Sickle-cell disease: Two new therapeutic strategies.

  Nalbandian RM, Henry RL, Murayama M. Nalbandian RM, et al. Lancet. 1978 Sep 9;2(8089):570-1. doi: 10.1016/s0140-6736(78)92898-2. Lancet. 1978. PMID: 79930 No abstract available.